RNS: RELEASE 21 MAY 2020
("ImmuPharma" or the "Company")
Notice of AGM and posting of Report & Accounts
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2019, and the Notice of Annual General Meeting has been posted to shareholders.
These documents are available, in electronic form, for download on the Company's website www.immupharma.co.uk.
ImmuPharma's Annual General Meeting (AGM) will be held on Thursday, 18 June 2020 @ 10.30am (BST) at: 50 Broadway, London SW1H 0RG.
We note the current issues surrounding COVID-19 (coronavirus) and the rapidly developing public health guidance in the UK at the time of writing. This includes the stringent requirements announced on 23 March 2020, which require UK nationals to stay at home except in tightly defined circumstances (which do not include attending an AGM), the social distancing and shielding guidance for those over the age of 70 or with underlying medical conditions, and the ban on all non-essential travel. The health and safety of our shareholders and colleagues is always our utmost priority.
As it is no longer possible to hold the AGM in the way that the Board had planned, we cannot allow shareholders to attend in person. Any shareholders attempting to gain access to the AGM will be excluded from the meeting on grounds of public safety. In the light of the above, we strongly encourage you to consider ensuring your vote is counted by submission of the proxy by post as detailed in the Notice of Annual General Meeting.
For further information please contact:
ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chairman
+ 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations
+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes
SI Capital (Joint Broker)
+44 (0) 203 368 8974
+44 (0) 203 815 8880
+44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor)
Degroof Petercam (Liquidity Provider)
Erik De Clippel
Gunther De Backer
+32 (0) 2 747 02 60
+32 (0) 2 287 95 34
+32 (0) 477 504 784
+32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 29 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US. For additional information about ImmuPharma please visit www.immupharma.com. ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.